Press release
Synairgen plc
('Synairgen' or the 'Company')
Exercise of Options
and Total Voting Rights
Southampton, UK - 12 August 2021: Synairgen plc (LSE: SNG), the respiratory company developing inhaled interferon beta (IFN-beta) for the treatment of severe viral lung infections, announces today that it has allotted 1,427,423 new ordinary shares of 1 pence each in the capital of the company ("Ordinary Shares") following the exercise of share options ("Option Exercise") by certain directors of the Company as set out in the table below.
The options that have been exercised were due to expire in September 2021. Certain of the new ordinary shares have been sold, at a price of 140p, to meet the tax and subscription costs associated with the exercise, with the remaining shares being retained by the directors. Following the exercise and subsequent sale, the holdings of the three directors are shown below:
| Director | New Ordinary Shares Issued | New Ordinary Shares Sold | Resultant Options | Resultant Ordinary Shares | % of Total Voting Rights |
| Richard Marsden | 538,063 | 296,959 | 2,279,513 | 995,771 | 0.49% |
| Dr Phillip Monk | 400,212 | 220,878 | 1,646,323 | 423,934 | 0.21% |
| John Ward | 489,148 | 269,963 | 1,772,958 | 734,092 | 0.36% |
Application has been made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on or around the 19th August 2021.
The new Ordinary Shares rank pari passu with the existing Ordinary Shares in the Company. Following the Option Exercise, the Company's issued share capital will consist of 201,341,825 Ordinary Shares. Accordingly, the figure of 201,341,825 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further enquiries, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Chief Financial Officer
Tel: + 44 (0) 23 8051 2800
finnCap (NOMAD and Joint Broker)
Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)
Alice Lane, Sunil de Silva (ECM)
Tel: + 44 (0) 20 7220 0500
Numis Securities Limited (Joint Broker)
James Black, Freddie Barnfield, Duncan Monteith
Tel: + 44 (0) 20 7260 1000
Consilium Strategic Communications (Financial Media and Investor Relations)
Mary-Jane Elliott, Jessica Hodgson, Carina Jurs
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
Notes for Editors
About Synairgen
Synairgen is a clinical-stage respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic.
Synairgen is currently focused on developing its product candidate, SNG001 (inhaled interferon beta) for the treatment of COVID-19. SNG001 is potentially the first host-targeted broad-spectrum antiviral treatment delivered directly into the lungs. The Company is evaluating nebulised SNG001 in its Phase III clinical programme, which has been deemed an Urgent Public Health study by the UK's National Institute for Health Research (NIHR). SNG001 has also been granted Fast Track status from the US Food and Drug Administration (FDA). In a Phase II trial, COVID-19 patients with marked/severe breathlessness demonstrated a threefold greater chance of recovery when treated with SNG001 versus placebo.
Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the company's obligations under Article 17 of MAR.
| 1. | Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA') | |||||
| a) | Name | Richard Marsden | ||||
| 2. | Reason for notification | |||||
| a) | Position / status | Chief Executive Officer | ||||
| b) | Initial notification / amendment | Initial Notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Synairgen plc | ||||
| b) | LEI | 213800IMMTOPPDF8HD24 | ||||
| 4. | Details of the transaction(s): | |||||
| a) | Description of the financial instrument
Identification code
| Exercise of options over ordinary shares of 1p each
GB00B0381Z20 | ||||
| b) | Nature of the transaction | Exercise of options | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information Aggregated volume Price | As above | ||||
| e) | Date of the transaction | 12 August 2021 | ||||
| f) | Place of the transaction | London AIM | ||||
| 1. | Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA') | |||||
| a) | Name | Richard Marsden | ||||
| 2. | Reason for notification | |||||
| a) | Position / status | Chief Executive Officer | ||||
| b) | Initial notification / amendment | Initial Notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Synairgen plc | ||||
| b) | LEI | 213800IMMTOPPDF8HD24 | ||||
| 4. | Details of the transaction(s): | |||||
| a) | Description of the financial instrument
Identification code
| Ordinary shares of 1p each
GB00B0381Z20 | ||||
| b) | Nature of the transaction | Sale of ordinary shares | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information Aggregated volume Price | As above | ||||
| e) | Date of the transaction | 12 August 2021 | ||||
| f) | Place of the transaction | London AIM | ||||
| 1. | Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA') | |||||
| a) | Name | Dr Phillip Monk | ||||
| 2. | Reason for notification | |||||
| a) | Position / status | Chief Scientific Officer | ||||
| b) | Initial notification / amendment | Initial Notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Synairgen plc | ||||
| b) | LEI | 213800IMMTOPPDF8HD24 | ||||
| 4. | Details of the transaction(s): | |||||
| a) | Description of the financial instrument
Identification code
| Exercise of options over ordinary shares of 1p each
GB00B0381Z20 | ||||
| b) | Nature of the transaction | Exercise of options | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information Aggregated volume Price | As above | ||||
| e) | Date of the transaction | 12 August 2021 | ||||
| f) | Place of the transaction | London AIM | ||||
| 1. | Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA') | |||||
| a) | Name | Dr Phillip Monk | ||||
| 2. | Reason for notification | |||||
| a) | Position / status | Chief Scientific Officer | ||||
| b) | Initial notification / amendment | Initial Notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Synairgen plc | ||||
| b) | LEI | 213800IMMTOPPDF8HD24 | ||||
| 4. | Details of the transaction(s): | |||||
| a) | Description of the financial instrument
Identification code
| Ordinary shares of 1p each
GB00B0381Z20 | ||||
| b) | Nature of the transaction | Sale of ordinary shares | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information Aggregated volume Price | As above | ||||
| e) | Date of the transaction | 12 August 2021 | ||||
| f) | Place of the transaction | London AIM | ||||
| 1. | Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA') | |||||
| a) | Name | John Ward | ||||
| 2. | Reason for notification | |||||
| a) | Position / status | Chief Financial Officer | ||||
| b) | Initial notification / amendment | Initial Notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Synairgen plc | ||||
| b) | LEI | 213800IMMTOPPDF8HD24 | ||||
| 4. | Details of the transaction(s): | |||||
| a) | Description of the financial instrument
Identification code
| Exercise of options over ordinary shares of 1p each
GB00B0381Z20 | ||||
| b) | Nature of the transaction | Exercise of options | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information Aggregated volume Price | As above | ||||
| e) | Date of the transaction | 12 August 2021 | ||||
| f) | Place of the transaction | London AIM | ||||
| 1. | Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA') | |||||
| a) | Name | John Ward | ||||
| 2. | Reason for notification | |||||
| a) | Position / status | Chief Financial Officer | ||||
| b) | Initial notification / amendment | Initial Notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Synairgen plc | ||||
| b) | LEI | 213800IMMTOPPDF8HD24 | ||||
| 4. | Details of the transaction(s): | |||||
| a) | Description of the financial instrument
Identification code
| Ordinary shares of 1p each
GB00B0381Z20 | ||||
| b) | Nature of the transaction | Sale of ordinary shares | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information Aggregated volume Price | As above | ||||
| e) | Date of the transaction | 12 August 2021 | ||||
| f) | Place of the transaction | London AIM | ||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
